A Phase II Evaluation of VEGF-Trap (NSC 724770, IND BB100137, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma.

Trial Profile

A Phase II Evaluation of VEGF-Trap (NSC 724770, IND BB100137, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2013

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Endometrial cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jul 2012 Planned end date changed from 1 Aug 2009 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 03 Mar 2010 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University, GOG0229F).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top